Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices

Leuk Lymphoma. 2017 Aug;58(8):1968-1972. doi: 10.1080/10428194.2016.1272688. Epub 2017 Jan 16.

Affiliations

¹ a Lymphoma Division, Blood and Marrow Transplantation Program, John Theurer Cancer Center , Hackensack University Medical Center , Hackensack , NJ , USA.
² b Millennium Pharmaceuticals Inc , Cambridge , MA , USA.
³ c Groupe d'analyse, Ltée , Montreal , QC , Canada.
⁴ d Analysis Group, Inc , Boston , MA , USA.

PMID: 28092998
DOI: 10.1080/10428194.2016.1272688

No abstract available

Publication types

Letter
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bortezomib / administration & dosage*
Bortezomib / adverse effects
Female
Humans
Injections, Subcutaneous
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / epidemiology*
Lymphoma, Mantle-Cell / pathology
Male
Practice Patterns, Physicians'*
Proteasome Inhibitors / administration & dosage*
Proteasome Inhibitors / adverse effects
Recurrence
Retreatment
Retrospective Studies
Survival Analysis
Treatment Outcome
United States / epidemiology

Substances

Antineoplastic Agents
Proteasome Inhibitors
Bortezomib